Clinical Trials Browser

Phase 3 × OTHER × Genitourinary × Clear all

NCT02064673 2026-03-17

Adjuvant Curcumin to Assess Recurrence Free Survival in Patients Who Have Had a Radical Prostatectomy

Phase 3 Recruiting

Prostatic Neoplasms

NCT05738694 2026-03-17

Neoadjuvant of Axitinib Plus PD-1 to Improve Disease Free Survival of Patients With Renal Cell Carcinoma

Phase 3 Recruiting

Carcinoma, Renal Cell

NCT07477626 2026-03-17

RADVAN

Phase 3 Active not recruiting

Prostatic Neoplasms

NCT03274687 2026-03-16

Hypofractionated Radiation Therapy or Conventional Radiation Therapy After Surgery in Treating Patients With Prostate Cancer

Phase 3 Completed

296 enrolled 29 charts

Prostate Adenocarcinoma

NCT06626022 2026-03-12

MUSIC-Screen

Phase 3 Recruiting

Prostate Cancer Screening

NCT06661720 2026-03-04

STRIKE

Phase 3 Recruiting

Carcinoma, Renal Cell

NCT06931340 2026-03-04

Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial

Phase 3 Recruiting

Prostatic Neoplasms

NCT07000084 2026-03-04

GAIN-BCG

Phase 3 Recruiting

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

NCT05154162 2026-03-03

PRIMARY2

Phase 3 Active not recruiting

Neoplasms, Prostatic Neoplasms

NCT03574571 2026-02-27

A Study to Test Radium-223 With Docetaxel in Patients With Prostate Cancer

Phase 3 Active not recruiting

Prostatic Neoplasms

NCT06959433 2026-02-27

Lu-177 PSMA Treatment in Cell Renal Carcinoma

Phase 3 Not yet recruiting

Carcinoma, Renal Cell, Kidney Neoplasms

NCT07427043 2026-02-23

ROPES

Phase 3 Recruiting

Prostatic Neoplasms

NCT07413120 2026-02-17

Efficacy and Safety of VasoClip® vs. WeckClip® for Robotic Urologic Surgery

Phase 3 Completed

Adenocarcinoma, Kidney Neoplasms, Prostatic Neoplasms

NCT06593665 2026-02-13

RPLND

Phase 3 Recruiting

Testicular Neoplasms

NCT06625034 2026-02-10

Radiation Therapy With RapidPlan Knowledge-based Planning vs Human-Driven Planning for Treatment of Prostate Cancer

Phase 3 Recruiting

Prostatic Neoplasms

NCT04455750 2026-02-05

CASPAR

Phase 3 Active not recruiting

Prostatic Neoplasms

NCT06349668 2026-02-05

SMILe

Phase 3 Recruiting

Kidney Neoplasms, Ureteral Neoplasms, Vesico-Ureteral Reflux, Nephrolithiasis

NCT04620239 2026-02-04

UCM301

Phase 3 Recruiting

Transitional Cell Cancer of Renal Pelvis and Ureter

NCT06563388 2026-02-04

ID-COMET

Phase 3 Recruiting

GastrointestinalGenitourinaryThoracic

Colonic Neoplasms, Lung Neoplasms, Prostatic Neoplasms

NCT05946213 2026-02-02

Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer

Phase 3 Recruiting

Prostatic Neoplasms

NCT07097142 2026-02-02

Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study

Phase 3 Recruiting

Urinary Bladder Neoplasms

NCT06825091 2026-01-28

ASPIRE

Phase 3 Recruiting

Localized Prostate Cancer

NCT06703476 2026-01-27

A Study of Surgical Techniques During Cystectomy

Phase 3 Recruiting

Urinary Bladder Neoplasms

NCT06205316 2026-01-20

SBRT Versus Hypofractionated Radiotherapy for Biochemically Recurrent or Oligometastatic Prostate Adenocarcinoma

Phase 3 Recruiting

Prostatic Neoplasms

NCT07092566 2026-01-20

R.E.C.K vs Exparel in Robotic Nephrectomy

Phase 3 Recruiting

Agnosia, Carcinoma, Renal Cell

NCT07346053 2026-01-16

Chrono-EVP

Phase 3 Not yet recruiting

Advanced Bladder Cancer

NCT03367702 2026-01-15

Stereotactic Body Radiation Therapy or Intensity-Modulated Radiation Therapy in Treating Patients With Stage IIA-B Prostate Cancer

Phase 3 Active not recruiting

Stage II Prostate Adenocarcinoma AJCC v7

NCT05838716 2026-01-15

ViPER

Phase 3 Recruiting

Prostatic Neoplasms

NCT06726421 2026-01-15

STROKER

Phase 3 Recruiting

Carcinoma, Renal Cell, Kidney Neoplasms

NCT04134260 2026-01-14

Testing the Addition of the Drug Apalutamide to the Usual Hormone Therapy and Radiation Therapy After Surgery for Prostate Cancer, INNOVATE Trial

Phase 3 Recruiting

Prostatic Neoplasms

NCT04513717 2026-01-14

Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial

Phase 3 Active not recruiting

Prostatic Neoplasms

NCT05050084 2026-01-14

Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance Trial

Phase 3 Recruiting

Prostate Adenocarcinoma

NCT06500455 2026-01-14

Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain

Phase 3 Recruiting

BreastCNSDermatologicGenitourinaryThoracic

Brain Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Lung Neoplasms, Melanoma, Neoplasm Metastasis

NCT07338981 2026-01-14

The Impact of Time-of-day-Dependent Administration of Nivolumab-Ipilimumab (ICI/ICI) Combination on Overall Survival in Adults With Advanced Kidney Cancer: A Pragmatic Multicenter, Randomized Controlled Trial.

Phase 3 Not yet recruiting

Advanced Kidney Cancer

NCT07333066 2026-01-12

REINFORCE

Phase 3 Not yet recruiting

Prostatic Neoplasms

NCT02051218 2025-12-30

Prevention of Symptomatic Skeletal Events With Denosumab Administered Every 4 Weeks Versus Every 12 Weeks

Phase 3 Active not recruiting

BreastGenitourinary

Breast Neoplasms, Prostatic Neoplasms

NCT06024772 2025-12-22

Multiparametric Ultrasound for the Diagnosis of Clinically Significant Prostate Cancer

Phase 3 Not yet recruiting

Prostatic Neoplasms

NCT03009981 2025-12-18

A Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer

Phase 3 Completed

Prostatic Neoplasms

NCT04157985 2025-12-11

Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors

Phase 3 Completed

DermatologicGastrointestinalGenitourinaryGynecologicHead & Neck

Squamous Cell Carcinoma of Head and Neck, Anus Neoplasms, Urinary Bladder Neoplasms, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Kidney Neoplasms, Melanoma, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Cholangiocarcinoma

NCT05726786 2025-12-09

INCyst

Phase 3 Recruiting

Cystitis, Hemorrhagic, Urinary Bladder Diseases, Urinary Bladder Neoplasms, Urinary Bladder, Neurogenic, Endometriosis, Cystitis, Interstitial, Malnutrition

NCT07268339 2025-12-05

TRAIN

Phase 3 Not yet recruiting

Non-Muscle Invasive Bladder Neoplasms

NCT07260435 2025-12-03

Apa/Enza-short

Phase 3 Recruiting

Prostatic Neoplasms

NCT02341989 2025-12-02

SWENOTECA-ABC

Phase 3 Active not recruiting

Recurrence, Testicular Neoplasms, Seminoma

NCT04394975 2025-11-28

Study to Evaluate the Efficacy and Safety of Toripalimab in Combination With Axitinib Versus Sunitinib Monotherapy in Advanced Renal Cell Cancer

Phase 3 Completed

Primary Disease: Unresectable or Metastatic Renal Cell Carcinoma Focus of the Study:PFS Assessed by IRC Per RECIST 1.1

NCT06525571 2025-11-18

Outcomes of High-risk Non-muscle Invasive Bladder Cancer Treated With Blue Light Resection

Phase 3 Recruiting

Urinary Bladder Neoplasms

NCT03987386 2025-11-12

Conventional or Hypofractionated Radiation Therapy in Treating Patients With Prostate Cancer

Phase 3 Active not recruiting

Prostatic Neoplasms

NCT01224288 2025-11-10

Dynamic Contrast Enhancement Computed Tomography for Evaluating Tumor Perfusion in Patients With Metastatic Renal Cell Carcinoma Receiving Targeted Therapies: Renal Cell Carcinoma (RCC) Scramble

Phase 3 Active not recruiting

Carcinoma, Renal Cell, Kidney Neoplasms

NCT06274047 2025-10-30

PROSTATE-IQ: Parallel RandOmized STudy of Personalized Apalutamide Treatment and Evaluation to Improve Quality of Life in Post-Operative Radiation With Androgen Axis Suppression. A Phase III Multi-center Study for Men With Detectable PSA After Prostatectomy for Prostate Cancer.

Phase 3 Recruiting

Prostatic Neoplasms

NCT06929286 2025-10-30

A Study Comparing Standard Treatments in People With Non-Muscle Invasive Bladder Cancer (NMIBC)

Phase 3 Recruiting

Non-Muscle Invasive Bladder Neoplasms

NCT07207824 2025-10-06

HERO

Phase 3 Not yet recruiting

Non-Muscle Invasive Bladder Neoplasms, Neoplasms